NO20060466L - Variable antibodies - Google Patents

Variable antibodies

Info

Publication number
NO20060466L
NO20060466L NO20060466A NO20060466A NO20060466L NO 20060466 L NO20060466 L NO 20060466L NO 20060466 A NO20060466 A NO 20060466A NO 20060466 A NO20060466 A NO 20060466A NO 20060466 L NO20060466 L NO 20060466L
Authority
NO
Norway
Prior art keywords
antibodies
factor viii
modified glycosylation
inhibitory
present
Prior art date
Application number
NO20060466A
Other languages
English (en)
Norwegian (no)
Inventor
Jean-Marie Saint-Remy
Marc Jacquemin
Original Assignee
D Collen Res Foundation Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0319118A external-priority patent/GB0319118D0/en
Priority claimed from GB0319345A external-priority patent/GB0319345D0/en
Application filed by D Collen Res Foundation Vzw filed Critical D Collen Res Foundation Vzw
Publication of NO20060466L publication Critical patent/NO20060466L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
NO20060466A 2003-08-14 2006-01-30 Variable antibodies NO20060466L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0319118A GB0319118D0 (en) 2003-08-14 2003-08-14 Variable antibodies
GB0319345A GB0319345D0 (en) 2003-08-18 2003-08-18 Variable antibodies
PCT/BE2004/000118 WO2005016455A2 (en) 2003-08-14 2004-08-16 Antibodies against factor viii with modified glycosylation in the variable region

Publications (1)

Publication Number Publication Date
NO20060466L true NO20060466L (no) 2006-04-24

Family

ID=34196257

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060466A NO20060466L (no) 2003-08-14 2006-01-30 Variable antibodies

Country Status (9)

Country Link
US (4) US7785594B2 (es)
EP (1) EP1706079B1 (es)
JP (1) JP4934796B2 (es)
AU (1) AU2004264265C1 (es)
CA (1) CA2535489C (es)
ES (1) ES2412489T3 (es)
IL (1) IL173557A (es)
NO (1) NO20060466L (es)
WO (1) WO2005016455A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016455A2 (en) 2003-08-14 2005-02-24 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
CA2517145C (en) * 2003-03-05 2017-08-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
FR2897868B1 (fr) * 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
CN105056231A (zh) * 2006-12-28 2015-11-18 詹森生物科技公司 用于产生脱唾液酸化免疫球蛋白的方法和载体
JP2010536363A (ja) * 2007-08-23 2010-12-02 エルエフビー バイオテクノロジース ファクターｖｉｉｉのｃ１ドメインに対する阻害抗体の阻害活性を中性化する抗イデオタイプ抗体
PL2242479T3 (pl) * 2007-12-28 2012-02-29 Baxalta Inc Filtracja białek z zastosowaniem przeciwciśnienia
JP2011518790A (ja) * 2008-04-23 2011-06-30 シムフォゲン・アクティーゼルスカブ ポリクローナルタンパク質を製造する方法
TR201820051T4 (tr) * 2008-06-19 2019-01-21 Prothix Bv Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
EP2233499A1 (en) * 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
RU2564131C2 (ru) 2009-07-10 2015-09-27 ТромбоДженикс НВ Варианты плазминогена и плазмина
ES2534911T3 (es) 2009-08-28 2015-04-30 Thrombogenics N.V. Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
DK2603528T3 (en) 2010-08-10 2016-11-28 Glycotope Gmbh FAB-glycosylated ANTIBODIES
BR112013017172A2 (pt) 2011-01-05 2016-10-11 Thrombogenics Nv variantes de plasminogênio e plasmina
CN102172359A (zh) * 2011-03-02 2011-09-07 张始状 腺苷与核苷组合在制备治疗肿瘤药物中的应用
WO2013024074A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
EP2785739B1 (en) 2011-12-01 2017-03-15 ThromboGenics N.V. Improving trabeculectomy outcome
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
KR20190094480A (ko) 2012-02-15 2019-08-13 바이오버라티브 테라퓨틱스 인크. 재조합 인자 viii 단백질
EP2855529A4 (en) * 2012-05-24 2015-12-09 Alexion Pharma Inc HUMANIZED ANTI-FACTOR B ANTIBODIES
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
JP6909203B2 (ja) 2015-08-03 2021-07-28 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
EP3426685A1 (en) 2016-03-10 2019-01-16 Oxurion NV Posterior ocular fibrosis inhibition by antagonizing placental growth factor
WO2018206734A1 (en) * 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains
DK3794042T3 (da) 2018-05-18 2024-04-15 Daiichi Sankyo Co Ltd Anti-muc1-exatecet-antistof-lægemiddelkonjugat

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451454A (en) 1981-06-16 1984-05-29 Wong Dennis W Prophylaxis and treatment of thromboembolic disorders in man and in warm-blooded animals with bicarbonate salts of alkali metals
IL82935A0 (en) 1986-08-12 1987-12-20 Phillips Petroleum Co Secretion of heterologous proteins from yeast
US5135854A (en) 1987-10-29 1992-08-04 Zymogenetics, Inc. Methods of regulating protein glycosylation
US5602015A (en) 1989-04-25 1997-02-11 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction
IE65172B1 (en) 1989-12-18 1995-10-04 Wellcome Found Viral agent
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US6127337A (en) 1993-10-25 2000-10-03 National Research Council Of Canada Bivalent thrombin inhibitors
IT1277827B1 (it) 1995-03-01 1997-11-12 Ministero Uni Ricerca Scient E Anticorpo monoclonale chimerico murino/umano o un suo frammento specifico per il recettore egf (egf-r)
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
ATE405649T1 (de) 1998-05-08 2008-09-15 Sanquin Bloedvoorziening Hemmstoff zur diagnose und behandlung von haemophilia a patienten
WO2000007626A1 (en) 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
DE19913707A1 (de) 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunadsorber zur Sepsistherapie
US7829085B2 (en) * 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
EP1194528B1 (en) 1999-07-14 2007-03-07 D. Collen Research Foundation vzw Monoclonal antibody for factor VIII, which even when present in molar excess inactivates factor VIII only in part and a method for producing such an antibody
WO2005016455A2 (en) * 2003-08-14 2005-02-24 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
US7067313B1 (en) 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
IL152775A0 (en) 2000-05-30 2003-06-24 Smithkline Beecham Corp Il-8 receptor antagonists
KR100799192B1 (ko) 2000-07-19 2008-01-31 미쯔비시 웰 파마 가부시키가이샤 히드록삼산계 설폰산 유도체 및 그의 의약 용도
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
ATE468136T1 (de) 2001-01-11 2010-06-15 D Collen Res Foundation Vzw Verfahren und pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung des syndroms der systemischen entzündlichen reaktion
ATE415472T1 (de) 2001-06-12 2008-12-15 Chemo Sero Therapeut Res Inst Humanantikörper gegen blutgerinnungsfaktor viii
WO2003048328A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
US20030175268A1 (en) 2002-01-11 2003-09-18 Saint-Remy Jean-Marie R. Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
US20050123997A1 (en) 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
EP1910420B1 (en) 2005-07-29 2011-05-18 Life Sciences Research Partners VZW Human inhibitory anti-factor viii antibodies binding to the a2 domain

Also Published As

Publication number Publication date
US7785594B2 (en) 2010-08-31
US20060292149A1 (en) 2006-12-28
US8282923B2 (en) 2012-10-09
ES2412489T3 (es) 2013-07-11
JP4934796B2 (ja) 2012-05-16
AU2004264265A1 (en) 2005-02-24
US8293234B2 (en) 2012-10-23
CA2535489C (en) 2014-09-30
IL173557A0 (en) 2006-07-05
US8277805B2 (en) 2012-10-02
CA2535489A1 (en) 2005-02-24
WO2005016455A3 (en) 2005-03-17
EP1706079A2 (en) 2006-10-04
JP2007502250A (ja) 2007-02-08
US20100266586A1 (en) 2010-10-21
WO2005016455A2 (en) 2005-02-24
IL173557A (en) 2012-09-24
AU2004264265B2 (en) 2009-09-17
US20100272715A1 (en) 2010-10-28
AU2004264265C1 (en) 2012-06-28
US20110070226A1 (en) 2011-03-24
EP1706079B1 (en) 2013-02-20

Similar Documents

Publication Publication Date Title
NO20060466L (no) Variable antibodies
NO20062767L (no) Immunoglobuliner
WO2002089738A3 (en) Proteomimetic compounds and methods
WO2004007520A3 (en) Methods and compositions for preventing oxidative degradation of proteins
ATE259215T1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
WO2005012242A3 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2002036142A3 (en) Compositions for inhibiting grb7
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2006012621A3 (en) Compositions and methods for regulating the alternative pathway of complement
WO2007027559A3 (en) Neuroprotective and neurorestorative methods and compositions
ATE407698T1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
WO2004031105A3 (en) Use of a33 antigens and jam-it
WO2002079474A3 (en) Human b7 polypeptides
WO2007067737A3 (en) Methods and compositions for inhibiting hiv infection
HK1063601A1 (en) Compositions and methods for treating hyperimmune response in the eye
WO2005070042A8 (en) Novel chemical compounds
ATE230414T1 (de) Mimetika von beta-faltblatt und verfahren zur verwendung davon
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
WO2004078142A3 (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions
WO2005087806A3 (en) Cd38 splice variant and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application